The development of new drugs is a life-and-death situation. There has always been a saying in the industry that the "Double Ten Law", that is, the development of a new drug requires an average of ten years of research and development cycle and a billion US dollars of research and development investment. The traditional R&D process is complex, and the cost continues to rise. Under the background of the continuous emergence of new targets and new technologies, and the increasingly fierce competition in the pharmaceutical industry, how can companies avoid homogenization and walk out of a differentiated route that suits their own characteristics? In the face of the current unmet clinical drug needs, how to find a path of characteristic development and innovation that is based in China and facing the world? How does the clinical value-oriented new drug development process mobilize multiple forces to solve clinical pain points and make better treatment plans more accessible?

In order to get through these "fogs", today (March 3, 2022), the 3rd (Shanghai) Biomedicine Co-hosted by Pharmaco and Lingkai Pharmaceuticals, and co-organized by Junda Hechuang and Pierre Fabre Pharmaceuticals (China) The Innovator Summit officially opened in Shanghai. The conference invited more than 50 practical experts in the field of biomedical research, development, operation and BD/investment to come to the scene, aiming to build a platform for the upstream and downstream of biomedicine to exchange industry trends and focus on industry innovation, attracting many industries. Colleagues to discuss innovation strategies, trends, technologies and experiences in the biopharmaceutical industry.